Richard Rode
Overview
Explore the profile of Richard Rode including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kolta S, Flandre P, Ngo Van P, Cohen-Codar I, Valantin M, Pintado C, et al.
Curr HIV Res
. 2011 Jan;
9(1):31-9.
PMID: 21198431
Given the decline in mortality among HIV-infected patients, it has become increasingly important to consider delayed disease-related and/or anti-HIV therapy-related adverse effects, such as lipodystrophy, when choosing initial therapy. Data...
2.
Grant P, Wong E, Rode R, Shafer R, De Luca A, Nadler J, et al.
Antimicrob Agents Chemother
. 2008 Aug;
52(11):4050-6.
PMID: 18710915
Several genotypic interpretation scores have been proposed for the evaluation of susceptibility to lopinavir/ritonavir (LPV/r) but have not been compared using an independent data set. This study was a retrospective...
3.
Rudin C, Burri M, Shen Y, Rode R, Nadal D
Pediatr Infect Dis J
. 2008 Apr;
27(5):431-7.
PMID: 18382386
Aim: To evaluate the long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced, initially protease inhibitor (PI)-naive, human immunodeficiency virus (HIV)-1-infected children. Methods: HIV-1-infected children enrolled in the...
4.
King M, Rode R, Cohen-Codar I, Calvez V, Marcelin A, Hanna G, et al.
Antimicrob Agents Chemother
. 2007 Jun;
51(9):3067-74.
PMID: 17576846
Several genotypic resistance algorithms have been proposed for quantitation of the degree of phenotypic resistance to the human immunodeficiency virus (HIV) protease inhibitor (PI) lopinavir (LPV), including the original LPV...
5.
Vrijens B, Goetghebeur E, de Klerk E, Rode R, Mayer S, Urquhart J
Stat Med
. 2005 Aug;
24(17):2719-31.
PMID: 16118813
The primary objective of this paper is to investigate the effect of adherence to prescribed antiretroviral therapy on virologic response measured repeatedly over time in HIV-infected patients. To this end...
6.
Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J
J Clin Pharmacol
. 2005 Mar;
45(4):461-7.
PMID: 15778427
Pharmacokinetic studies rely on blood sampling at times relative to predefined dosing intervals. Intensive sampling is often done under direct observation of dose taking, which, though costly, virtually eliminates uncertainty...
7.
Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, et al.
Antimicrob Agents Chemother
. 2002 Dec;
47(1):350-9.
PMID: 12499212
The steady-state pharmacokinetics and pharmacodynamics of two oral doses of lopinavir-ritonavir (lopinavir/r; 400/100 and 533/133 mg) twice daily (BID) when dosed in combination with efavirenz, plus two nucleoside reverse transcriptase...
8.
Kempf D, Isaacson J, King M, Brun S, Sylte J, Richards B, et al.
Antivir Ther
. 2002 Dec;
7(3):165-74.
PMID: 12487383
The virological response of multiple protease inhibitor-experienced, non-nucleoside reverse transcriptase inhibitor-naive, HIV-1-infected subjects was examined with respect to baseline viral phenotype and genotype through 72 weeks of therapy with lopinavir/ritonavir...
9.
Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, et al.
Antimicrob Agents Chemother
. 2002 Nov;
46(12):3907-16.
PMID: 12435695
Depending on the degree of underlying resistance present, optimization of the pharmacokinetics of protease inhibitors may result in improved virologic suppression. Thirty-seven human immunodeficiency virus (HIV)-infected subjects who had chronic...